Royalty Pharma Plc Stock Analysis

Royalty Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Royalty Pharma Plc last dividend was issued on the 15th of November 2024. The entity had 1:4 split on the 15th of October 2010. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company was founded in 1996 and is based in New York, New York. Royalty Pharma is traded on NASDAQ Exchange in the United States. To find out more about Royalty Pharma Plc contact the company at 212 883 0200 or learn more at https://www.royaltypharma.com.

Royalty Pharma Plc Investment Alerts

Royalty Pharma Plc Upcoming and Recent Events

Royalty Largest EPS Surprises

View All Earnings Estimates

Royalty Pharma Environmental, Social, and Governance (ESG) Scores

Royalty Stock Institutional Investors

Note, although Royalty Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Royalty Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 15.67 B.

Royalty Profitablity

The company has Profit Margin (PM) of 0.51 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 1.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $1.3.

Management Efficiency

Royalty Pharma Plc has return on total asset (ROA) of 0.0569 % which means that it generated a profit of $0.0569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1728 %, meaning that it created $0.1728 on every $100 dollars invested by stockholders. Royalty Pharma's management efficiency ratios could be used to measure how well Royalty Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.09 in 2024. Return On Capital Employed is likely to rise to 0.11 in 2024. At this time, Royalty Pharma's Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 16.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 1.7 M in 2024.

Technical Drivers

As of the 28th of November, Royalty Pharma holds the Information Ratio of (0.21), risk adjusted performance of (0.07), and Standard Deviation of 0.9966. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Royalty Pharma, as well as the relationship between them.

Royalty Pharma Plc Price Movement Analysis

Royalty Pharma Plc Insider Trading Activities

Royalty Pharma Outstanding Bonds

Royalty Pharma Predictive Daily Indicators

Royalty Pharma Corporate Filings

Royalty Pharma Forecast Models

Royalty Pharma's time-series forecasting models are one of many Royalty Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Royalty Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Royalty Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Royalty shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Royalty Pharma. By using and applying Royalty Stock analysis, traders can create a robust methodology for identifying Royalty entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Royalty analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Royalty analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Royalty Pharma Plc stock analysis indicators help investors evaluate how Royalty Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Royalty Pharma shares will generate the highest return on investment. By understating and applying Royalty Pharma stock analysis, traders can identify Royalty Pharma position entry and exit signals to maximize returns.

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.